Direkt zum Inhalt
Merck
  • Induction of antinociceptive tolerance to the chronic intrathecal administration of apelin-13 in rat.

Induction of antinociceptive tolerance to the chronic intrathecal administration of apelin-13 in rat.

Neuropeptides (2016-08-21)
Elham Abbasloo, Hamid Najafipour, Saeed Esmaeili-Mahani
ZUSAMMENFASSUNG

Pain represents a major contributing factor to the individual's quality of life. Although pain killers as opioids, endogenous or exogenous peptides can decrease pain perception, the chronic use of them leads to antinociceptive tolerance. It has been demonstrated that neuropeptide apelin has potent antinoceptive effect. However, the possibility of the induction of its antinociceptive tolerance has not yet been clarified. The tail-flick test was used to assess the nociceptive threshold. All experiments were carried out on male Wistar rats which received intrathecal apelin for 7days. To determine the role of apelin and opioid receptors on the development of apelin analgesic tolerance, their receptor antagonists (F-13 A and naloxone, respectively) were injected simultaneously with apelin. The lumbar spinal cord was assayed to determine apelin receptor levels by the western blotting method. Plasma corticosterone levels were assayed using ELISA. Results showed that apelin (3μg/rat) induced strong thermal antinociception. In addition, chronic apelin produced tolerance to its antinociceptive effect and down regulated spinal apelin receptor. F-13 A and naloxone could inhibit apelin tolerance development. The corticosterone levels did not change following drug administration. Taken together, the data indicated that apelin like other analgesic drugs leads to the induction of side effects such as analgesic tolerance which is mediated partly via the apelin and opioid receptors activation.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
RIPA-Puffer
Sigma-Aldrich
[Ala13]-Apelin-13 trifluoroacetate salt, ≥96% (HPLC)